David Gill, the Chief Financial Officer of Juvenescence, is a Chartered Accountant (FCA) with extensive experience in both the US and UK in private and listed biotech companies.

Previously Group Controller of the company, David was attracted to Juvenescence because of its exciting programmes. He says, “targeting both prevention and treatment of age-related diseases, Juvenescence has a diverse pipeline that offers unique and exciting opportunities to investors.”

Before joining Juvenescence, David was Head of Finance at NASDAQ-listed Silence Therapeutics in London, an RNAi biotech company. Prior to this he was at PwC for 10 years, most recently having worked on GlaxoSmithKline.